Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 expression + EGFR mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4